Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
Matinas BioPharma received a non-compliance notice from the NYSE American because it failed to meet continued listing standards regarding stockholders' equity. As of March 31, 2026, the company held $3.02 million in equity, below the $4.0 million requirement, and has reported losses in five of its most recent fiscal years.
Key figures
- Plan period deadline
- October 2, 2027
- Stockholders equity dec 2025
- $4.83 million
- Stockholders equity mar 2026
- $3.02 million
- Required equity section 1003 a ii
- $4.0 million
- Required equity section 1003 a iii
- $6.0 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.